Price
Target price
€2.00
€2.00
-7.620%
-0.165
-7.620%
€3.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cardiol Therapeutics Inc. Stock
Cardiol Therapeutics Inc. took a tumble today and lost -€0.165 (-7.620%).
The community is currently still undecided about Cardiol Therapeutics Inc. with 1 Buy predictions and 1 Sell predictions.
With a target price of 3 € there is a hugely positive potential of 50.3% for Cardiol Therapeutics Inc. compared to the current price of 2.0 €.
Pros and Cons of Cardiol Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
- Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients with recurrent pericarditis, with topline results expected in Q2 2024
-
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Topline Results Expected in Q2 2024
This is a Designated News Release.
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”),